These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37545624)

  • 1. Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report.
    Fan S; He L; Sang D
    Oncol Lett; 2023 Aug; 26(2):359. PubMed ID: 37545624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review.
    Lan Y; Zhao J; Zhao F; Li J; Li X
    Front Oncol; 2024; 14():1338661. PubMed ID: 38952555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.
    Feng H; Bi S; Sun S; Yang H; Zhou H; Mao J; Li N; Yang F
    Front Oncol; 2024; 14():1367140. PubMed ID: 39351350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
    Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
    Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of disitamab vedotin after trastuzumab for HER2 positive breast cancer: a real-world data of retrospective study.
    Li C; Sun L; Liu Z; Sun H; Wang X; Yu Q; Yu Z
    Am J Cancer Res; 2024; 14(2):869-879. PubMed ID: 38455400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
    Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
    Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
    Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
    Shi F; Liu Y; Zhou X; Shen P; Xue R; Zhang M
    Drug Deliv; 2022 Dec; 29(1):1335-1344. PubMed ID: 35506447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
    Qu F; Liu Q; Lu R; Li W
    Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
    Huang L; Wang R; Xie K; Zhang J; Tao F; Pi C; Feng Y; Gu H; Fang J
    Breast Cancer Res Treat; 2022 Jan; 191(1):51-61. PubMed ID: 34657203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
    Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
    EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.
    Chen M; Huang R; Chen R; Pan F; Shen X; Li H; Rong Q; An X; Xue C; Shi Y
    Oncologist; 2024 Aug; 29(8):e957-e966. PubMed ID: 38574190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
    Hu Y; Zhu Y; Wei X; Tang C; Zhang W
    Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
    Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
    Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
    Lee J; Kida K; Koh J; Liu H; Manyam GC; Gi YJ; Rampa DR; Multani AS; Wang J; Jayachandran G; Lee DW; Reuben JM; Sahin A; Huo L; Tripathy D; Im SA; Ueno NT
    J Exp Clin Cancer Res; 2024 Aug; 43(1):236. PubMed ID: 39164784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
    Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
    BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.
    Yu J; Fang T; Yun C; Liu X; Cai X
    Front Mol Biosci; 2022; 9():847835. PubMed ID: 35295841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
    D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
    J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
    Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
    Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.